Bryan Garnier - VOLUNTIS (VTX.PA) VOLUNTIS: Shift to oncology: challenging deployment of Oleena following FDA approval? | NEUTRAL | EUR6.8 vs. EUR8 (+527%)

Report

Bryan Garnier

Hugo Solvet

VOLUNTIS: Shift to oncology: challenging deployment of Oleena following FDA approval? | NEUTRAL | EUR6.8 vs. EUR8 (+527%)

VOLUNTIS - NEUTRAL | EUR6.8 vs. EUR8 (+527%)
Shift to oncology: challenging deployment of Oleena following FDA approval?

Oleena approved by the FDA
A whole new marketing strategy
Anticipating limited commercial traction at launch
What about diabetes and contracts with PBMs?
FV down to EUR6.8 reflects slow development in diabetes

01/08/2019 3 EN

Underlying

VOLUNTIS

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Hugo Solvet

Other Reports on these Companies

Bryan Garnier

From 3rd May, 2022 Voluntis will not be included in our research universe due to the proposed de-listing.

MedTech End of coverage From 3rd May, 2022 Voluntis will not be included in our research universe due to the proposed de-listing.

May 3, 2022 May 3, 2022 1 EN

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

VOLUNTIS (CORPORATE, TP EUR11) | AptarGroup and Voluntis in discussions for a EUR8.7/share takeover:

June 23, 2021 June 23, 2021 3 EN

Eutelsat: EUR1.35bn raise and step towards becoming a strategic French asset

Eutelsat has announced a EUR1.35bn equity raise, including a EUR716m reserved capital increase at EUR4/share and a EUR634m rights issue, underwritten by the French State, Bharti, CMA CGM, and FSP. The capital raise is not unexpected, given prior rumours and Eutelsat's financing needs. The higher su

June 20, 2025 June 20, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Camurus: CAM2029 Ph2/3 in PLD met primary endpoint, follow up Ph3 TBD

Camurus reported topline data from its phase 2/3 POSITANO study (n=71) evaluating CAM2029 in PLD which met the primary endpoint showing stat. sig. relative reduction of the liver volume (htTLV) from baseline to week 53 of 4.3% (p=0.044) vs pbo, with corresponding relative reduction in total liver c

June 18, 2025 June 18, 2025 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Medincell FY24: Uzedy TRx growth momentum; Runway to profitability

Medincell’s FY24 results primarily focused on balance sheet items and a recap of corporate achievements. Importantly, Uzedy’s TRx data continues to show sustained momentum, which we view as a key metric to forecast future growth - we maintain our expectation of accelerating sales into FY25 (FYe: US

June 18, 2025 June 18, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

VOLUNTIS: Shift to oncology: challenging deployment of Oleena following FDA approval? | NEUTRAL | EUR6.8 vs. EUR8 (+527%)

From 3rd May, 2022 Voluntis will not be included in our research universe due to the proposed de-listing.

Monthly LMI Update Independent Investment Research

VOLUNTIS (CORPORATE, TP EUR11) | AptarGroup and Voluntis in discussions for a EUR8.7/share takeover:

Eutelsat: EUR1.35bn raise and step towards becoming a strategic French asset

Camurus: CAM2029 Ph2/3 in PLD met primary endpoint, follow up Ph3 TBD

Medincell FY24: Uzedy TRx growth momentum; Runway to profitability

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe